Home  /  Resource Library  /  Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after >2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after >2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

ASH 2023